Milan, Italy, March 5, 2020 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Milan, Italy and Morristown, NJ, USA, Feb. 17, 2020 -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
February 04, 2020 – Milan, Italy and Morristown, NJ – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
Milan, Italy and Morristown, NJ, USA, January 9, 2020 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
Meeting expected to occur within thirty days of FDA’s receipt of the meeting request and meeting package
STARS (Sarizotan Treatment of Apneas in Rett Syndrome) clinical study to
Milan, Italy – November 25, 2019 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Milan, Italy and Morristown, NJ, USA, November 19, 2019 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development
Sponsoring the largest, most comprehensive qualitative study ever to examine the burden of Rett syndrome on individuals and their caregivers
Survey outreach to begin in the United
Milan, Italy, September 20, 2019 – Newron Pharmaceuticals S.pA. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy – September 12, 2019 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
